• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does CareDx’s Profit Jump And Higher 2026 Outlook Change The Bull Case For CDNA?

    Simply Wall St·08/12/2026 21:27:57
    Listen to the news
    • In late July 2026, CareDx, Inc. reported second-quarter revenue of US$131.95 million and net income of US$110.64 million, a shift from a loss a year earlier, and raised its full-year 2026 revenue outlook to US$490–500 million.
    • The company paired its earnings strength with capital moves, completing a US$50.00 million buyback program while also filing an US$80.30 million shelf registration for 2,267,800 ESOP-related common shares, highlighting active balance sheet and employee ownership management.
    • We’ll now examine how CareDx’s raised 2026 revenue guidance reshapes its existing investment narrative around growth, margins, and reimbursement risk.

    Uncover the next big thing with 19 elite penny stocks that balance risk and reward.

    CareDx Investment Narrative Recap

    To own CareDx today, you need to believe its transplant diagnostics franchise can keep converting reimbursement coverage into sustainable profits despite policy and competitive pressure. The raised 2026 revenue outlook to US$490–500 million supports the near term growth catalyst, but the biggest current risk remains how evolving Medicare rules, including new LCD limits and any future bundled payments, could affect test volumes, pricing, and ultimately the durability of this profit recovery.

    Among the recent announcements, the Medicare LCD finalized in mid July stands out as most relevant. It confirms coverage and sets explicit frequency limits for key tests like AlloSure Kidney, AlloMap and AlloSure Heart, and AlloSure Lung starting August 30, 2026. This clarity frames both the opportunity in covered surveillance volumes and the ceiling on utilization, directly intersecting with the upgraded 2026 revenue guidance and sharpening the focus on reimbursement risk as a central driver of the story.

    Yet even with stronger guidance and solid earnings, the possibility of further Medicare changes that tighten test frequency or move more aggressively to bundled payments is something investors should be aware of...

    Read the full narrative on CareDx (it's free!)

    CareDx's narrative projects $616.7 million revenue and $18.9 million earnings by 2029. This requires 10.4% yearly revenue growth and a $92.1 million earnings decrease from $111.0 million today.

    Uncover how CareDx's forecasts yield a $52.33 fair value, a 11% upside to its current price.

    Exploring Other Perspectives

    CDNA 1-Year Stock Price Chart
    CDNA 1-Year Stock Price Chart

    Some of the lowest ranked analysts came in with a far more cautious view, assuming revenue of about US$489 million and earnings near US$65 million by 2029, and they focus heavily on the risk that consolidation among payers and health systems could pressure pricing even more than reimbursement policy alone. Their stance highlights how sharply opinions can differ, and why it may be worth comparing this new earnings news against several contrasting scenarios before you decide what you believe.

    Explore 4 other fair value estimates on CareDx - why the stock might be worth 41% less than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Seeking Other Investments?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.